Grown Rogue International (GRUSF) Depreciation & Amortization (CF) (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Depreciation & Amortization (CF) came in at $91162.0 in Q1 2026, down 20.13% year-on-year from $114135.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$354.5 billion in Q4 2025.
Grown Rogue International (GRUSF) Depreciation & Amortization (CF) (2009 - 2026) Analysis & Trends
Grown Rogue International's Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $91162.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 20.13% year-over-year to $91162.0 in Q1 2026; TTM through Mar 2026 was -$233.3 billion, a 189.13% decrease from a year earlier, with the FY2025 full-year figure at $702258.0, down 29.31% from the prior year.
- Depreciation & Amortization (CF) climbed to $91162.0 in Q1 2026 per GRUSF's latest filing, from -$354.5 billion in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $261.8 billion in Q3 2024 and bottomed at -$354.5 billion in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $119159.0 (2025), against an average of $2.2 billion.
- Across the five-year window, Depreciation & Amortization (CF) plunged 58.18% in 2022 and jumped 122.34% in 2023, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $52010.0 in 2022, then surged by 790.22% to $463002.0 in 2023, then jumped by 56533133.12% to $261.8 billion in 2024, then plunged by 235.44% to -$354.5 billion in 2025, then jumped by 100.0% to $91162.0 in 2026.
- Per Business Quant, the three latest GRUSF Depreciation & Amortization (CF) figures stand at $91162.0 (Q1 2026), -$354.5 billion (Q4 2025), and $121.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 91,162.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91,162.00 |
| Mar 31, 2026 | 91,162.00 |
| Dec 31, 2025 | -354.53 Bn |
| Dec 31, 2025 | -354.53 Bn |
| Sep 30, 2025 | 121.23 Bn |
| Sep 30, 2025 | 121.23 Bn |
| Jun 30, 2025 | 119,159.00 |
| Jun 30, 2025 | 119,159.00 |
| Mar 31, 2025 | 114,135.00 |
| Mar 31, 2025 | 114,135.00 |
| Sep 30, 2024 | 261.75 Bn |
| Sep 30, 2024 | 261.75 Bn |
| Jun 30, 2024 | 154,484.88 |
| Jun 30, 2024 | 154,484.88 |
| Mar 31, 2024 | 255,052.00 |
| Mar 31, 2024 | 255,052.00 |
| Oct 31, 2023 | 463,002.00 |
| Oct 31, 2023 | 463,002.00 |
| Jul 31, 2023 | 264,183.00 |
| Jul 31, 2023 | 264,183.00 |